SecBot SecBot
SECBOTREPLAY Home › Report › BIOA

BIOA · BioAge Labs announced positive Phase 1 results for BGE-102, its oral…

BioAge Labs, Inc. · PRESS-RELEASE filed Apr 21, 2026 at 07:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Apr 21, 2026 at 07:00 ET

BioAge Labs announced positive Phase 1 results for BGE-102, its oral NLRP3 inhibitor, showing profound reductions in hsCRP and other inflammatory biomarkers in obese participants with elevated inflammation. The company plans to initiate Phase 2 proof-of-concept trials in cardiovascular risk and diabetic macular edema by mid-2026, with data expected by end-2026 and mid-2027, respectively.

  • BGE-102 achieved 85% median hsCRP reduction at 60 mg dose and 86% at 120 mg dose in participants with obesity and elevated inflammation
  • 87% of participants on 60 mg dose achieved normalized hsCRP (<2 mg/L) by Day 21
  • Drug was well tolerated with no serious adverse events or discontinuations
  • Phase 2 cardiovascular risk trial planned for initiation in first half of 2026, with data by end of year

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access